Long-Term Obligation (Narrative) (Details) - USD ($)
|
1 Months Ended |
12 Months Ended |
41 Months Ended |
|
|
Feb. 29, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Dec. 31, 2015 |
Dec. 31, 2012 |
Aug. 31, 2012 |
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
| Aggregate payments to long-term obligations |
|
$ 9,207,000
|
$ 4,856,000
|
$ 1,025,000
|
|
|
|
| Accretion of interest expense |
|
2,848,000
|
3,678,000
|
4,410,000
|
|
|
|
| Cash and cash equivalents |
|
40,435,000
|
24,248,000
|
$ 54,877,000
|
$ 40,435,000
|
$ 93,032,000
|
|
| Financing Agreement with Biopharma |
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
| Cumulative payments to be made under financing agreement |
|
45,000,000
|
|
|
$ 45,000,000
|
|
$ 45,000,000
|
| Aggregate payments to long-term obligations |
|
$ 15,100,000
|
|
|
|
|
|
| Payment obligation based on a percentage of net product sales |
|
20.00%
|
|
|
|
|
|
| Percentage of payments received for upfront, milestone or other contingent fees |
|
20.00%
|
|
|
20.00%
|
|
|
| Interest expense on long-term obligation |
|
$ 2,800,000
|
3,700,000
|
|
|
|
|
| Accretion of interest expense |
|
|
|
|
$ 12,600,000
|
|
|
| Long term debt obligation |
|
27,500,000
|
$ 33,900,000
|
|
27,500,000
|
|
30,000,000
|
| Issuance costs capitalized |
|
140,000
|
|
|
140,000
|
|
|
| Unamortized issuance cost |
|
35,000
|
|
|
35,000
|
|
|
| Financing Agreement with Biopharma | Subsequent Events |
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
| Aggregate payments to long-term obligations |
$ 3,000,000
|
|
|
|
|
|
|
| Minimum | Financing Agreement with Biopharma | Cash Required Under Debt Covenants |
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
| Cash and cash equivalents |
|
50,000,000
|
|
|
50,000,000
|
|
|
| Maximum | Financing Agreement with Biopharma |
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
| Cumulative payments to be made under financing agreement |
|
$ 45,000,000
|
|
|
$ 45,000,000
|
|
$ 45,000,000
|
| Payment obligation based on a percentage of net product sales |
|
50.00%
|
|
|
|
|
|